Johnson & Johnson (NYSE:JNJ) Releases FY 2025 Earnings Guidance

Johnson & Johnson (NYSE:JNJ - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 10.500-10.700 for the period, compared to the consensus estimate of 10.500. The company issued revenue guidance of $91.0 billion-$91.8 billion, compared to the consensus revenue estimate of $90.3 billion.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Stifel Nicolaus lowered their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research note on Thursday, January 23rd. Raymond James dropped their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Wednesday. Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $171.82.

Johnson & Johnson Trading Up 2.3 %

Shares of Johnson & Johnson stock traded up $3.51 during mid-day trading on Friday, hitting $157.42. The stock had a trading volume of 10,972,370 shares, compared to its average volume of 7,953,112. The firm has a market cap of $379.37 billion, a P/E ratio of 23.67, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm has a 50-day moving average of $159.49 and a two-hundred day moving average of $155.03. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a $1.30 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.30%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is currently 74.59%.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares of the company's stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Johnson & Johnson stock. Brighton Jones LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,876 shares of the company's stock after purchasing an additional 6,332 shares during the period. Brighton Jones LLC's holdings in Johnson & Johnson were worth $7,502,000 at the end of the most recent quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.